In last trading session, Fate Therapeutics Inc (NASDAQ:FATE) saw 3.14 million shares changing hands with its beta currently measuring 2.26. Company’s recent per share price level of $1.54 trading at -$0.17 or -9.65% at ring of the bell on the day assigns it a market valuation of $175.97M. That closing price of FATE’s stock is at a discount of -473.38% from its 52-week high price of $8.83 and is indicating a premium of 32.47% from its 52-week low price of $1.04.

For Fate Therapeutics Inc (FATE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.44. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.43 in the current quarter.

Fate Therapeutics Inc (NASDAQ:FATE) trade information

Upright in the red during last session for losing -9.65%, in the last five days FATE remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $1.54 price level, adding 14.92% to its value on the day. Fate Therapeutics Inc’s shares saw a change of -6.36% in year-to-date performance and have moved 23.60% in past 5-day. Fate Therapeutics Inc (NASDAQ:FATE) showed a performance of 17.05% in past 30-days.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 69.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -224.68% in reaching the projected high whereas dropping to the targeted low would mean a loss of -224.68% for stock’s current value.

Fate Therapeutics Inc (FATE) estimates and forecasts

This year revenue growth is estimated to fall -78.70% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.51M for the same. And 9 analysts are in estimates of company making revenue of 1.24M in the next quarter. Company posted 1.68M and 1.93M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -6.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 0.43% while estimates for its earnings growth in next 5 years are of 1.90%.

Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders

REDMILE GROUP, LLC is the top institutional holder at FATE for having 13.17 million shares of worth $43.19 million. And as of 2024-06-30, it was holding 11.2107 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.4544 of outstanding shares, having a total worth of $34.67 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.05 shares of worth $4.71 million or 2.68% of the total outstanding shares. The later fund manager was in possession of 2.8 shares on Nov 30, 2024 , making its stake of worth around $4.33 million in the company or a holder of 2.46% of company’s stock.